Zarejestruj się, aby utworzyć powiadomienia dla instrumentów,
wydarzeń ekonomicznych i analiz obserwowanych autorów
Darmowa rejestracja Posiadasz już konto? Logowanie
Notowania
Wszystkie aktywa
- Wszystkie aktywa
- Indeksy
- Akcje
- ETF
- Fundusze
- Towary
- Waluty
- Krypto
- Obligacje
- Certyfikaty
Prosimy o wyszukanie innej nazwy
Nowość! 💥 Skorzystaj z ProPicks i zobacz strategię, która pokonała S&P 500 o +1,183% Zdobądź 40% ZNIŻKĘ
Axa Framlington Biotech Fund - R Accumulation (0P0000XMRD)
Dodaj/usuń z portfela
Dodaj do listy obserwowanych
5,177
+0,040
+0,82%
- Ocena firmy Morningstar:
- Aktywa ogółem: 343,19M
AXA Framlington Biotech Fund GBP Z Acc
5,177
+0,040
+0,82%
- Przegląd
- Wykres
- Wiadomości i analizy
- Techniczna
- Forum
- Przegląd
- Profil
- Dane historyczne
- Aktywa
Przegląd 0P0000XMRD
Na tej stronie znajdziesz szczegółowy profil Axa Framlington Biotech Fund - R Accumulation. Uzyskaj informacje m.in. o kluczowych członkach kierownictwa, sumie aktywów, strategii inwestycyjnej i danych kontaktowych 0P0000XMRD.
Informacje kontaktowe
Adres
100, Esplanade du Général de Gaulle
Paris, 92932
France
Paris, 92932
France
Telefon
+33 1 44 45 70 00
Fax
Paris
Internet
www.axa-im-international.com
Kierownictwo najwyższego szczebla
| Nazwa | Tytuł | Od | Do |
|---|---|---|---|
| Cinney Zhang | - | 2023 | Teraz |
| Linden Thomson | - | 2012 | Teraz |
| Peter Hughes | Portfolio Manager | 2001 | 2023 |
| Biografia | Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News. | ||
| Dani Saurymper | - | 2015 | 2020 |
| Biografia | Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare. | ||
| Gemma Game | - | 2011 | 2015 |
| Deane Donnigan | clinical Specialist | 2010 | 2011 |
| Biografia | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. | ||
| Andy Smith | Portfolio manager | 2009 | 2010 |
| Biografia | Andy joined AXA Framlington in April 2008 as Portfolio Manager within the healthcare team with specific responsibility for the AXA Framlington Biotech Fund. Previously, he spent three years at SV Life Sciences where he was responsible for managing a global biotechnology investment fund. From 2004 to 2005 he worked at Schroders as Director and Fund Manager, Global Equities. Between 2002 and 2004 he worked within the Asset Management division of the 3i Group as Investment Manager and then Director. | ||
| Deane Donnigan | clinical Specialist | 2007 | 2009 |
| Biografia | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. | ||
| Gareth Powell | Portfolio Manager | 2004 | 2007 |
| Biografia | Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder. | ||
| Antony Milford | - | 2001 | 2007 |
Napisz co myślisz o Axa Framlington Biotech Fund - R Accumulation
Czy na pewno chcesz usunąć ten wykres?
Usuń Anuluj
Zastąpić dołączony wykres nowym wykresem?
Zastąp Anuluj
Wytyczne do komentarzy
Dodaj wykres do komentarza
Potwierdź zablokowanie
Czy na pewno chcesz zablokować %USER_NAME%?
Po włączeniu opcji blokady, ani Ty ani %USER_NAME% nie będziecie mogli zobaczyć swoich postów na Investing.com.
%USER_NAME% został pomyślnie dodany do Twojej Listy zablokowanych
Ponieważ właśnie odblokowałeś tę osobę, aby móc ponownie ją zablokować musi minąć 48 godzin.
Zgłoś ten komentarz
Uważam, że ten komentarz jest:
Komentarz zgłoszony
Dziękujemy!
Twoje zgłoszenie zostało wysłane do naszych moderatorów w celu rewizji